article thumbnail

The imperative of fridge-free vaccines

European Pharmaceutical Review

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 102
article thumbnail

RVAC and University of Pennsylvania to develop mRNA vaccines

Pharmaceutical Technology

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Large UK study suggests vaccination helps treat long COVID

pharmaphorum

The likelihood of long COVID symptoms was found to decrease after COVID-19 vaccination, and evidence pointed to an even greater improvement after a second dose. However, the authors say more data is needed before vaccination can be considered a treatment for the condition.

Vaccines 115
article thumbnail

The 2023-2024 Flu Season: What Pharmacists Need to Know

Digital Pharmacist

The most effective preventive measure against the flu is getting an annual flu vaccine. Getting Vaccinated for the Flu The CDC says ideally, everyone who is eligible for a flu vaccine should be vaccinated by the end of October – the ideal time to get vaccinated being September or October.

article thumbnail

Gritstone bio supports mRNA Covid-19 vaccine plans with Phase I publication

Pharmaceutical Technology

Gritstone bio has reported interim results from an ongoing Phase 1 study evaluating the company’s self-amplifying mRNA (samRNA) vaccine as a boost against Covid-19 (CORAL-BOOST). The Phase I CORAL-BOOST dose-escalation trial (NCT05148962) evaluated Gritstone’s samRNA candidate (GRT-R910) in previously vaccinated healthy older adults.

article thumbnail

Digital innovation drives vaccine development

pharmaphorum

It is becoming increasingly important for people all over the world to understand the importance of vaccines and to have access to the vaccines they need – especially with digital innovation driving new vaccine development. Pfizer’s Josh Raysman, Saad Saeed, and Shanaya Deboo discuss vaccine awareness, access, and innovation.

article thumbnail

Pfizer/BioNTech say COVID-19 vaccine works against UK variant

pharmaphorum

Laboratory studies have confirmed that antibodies stimulated by Pfizer and BioNTech’s COVID-19 vaccine can neutralise the new, more transmissible variant of SARS-CoV-2 identified in the UK. That suggests that patients could get SARS-CoV-2 twice, but also that the current crop of vaccines may not be as effective.